To address tumor heterogeneity, Ma et al. developed a heterodimer that targets both PSMA and NTR1, which showed prominent uptake in NTR1-positive/PSMA-negative and PSMA-positive/NTR1-negative prostate cancer xenografts [66]. Here, FOLH1 is linked to prostate cancer.